Education
About Us
Working with TipRanks
Follow Us
Valneva SE (GB:0OB3)
LSE:0OB3
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.13Last Year’s EPS
0.41Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: 3.75%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
Valneva reported strong financial and regulatory achievements in 2024, with significant sales growth and a strong cash position. However, the slower-than-expected ramp-up of IXCHIQ and regulatory delays in Brazil are notable challenges. Despite these lowlights, the company's strategic initiatives and successful financial transactions provide a positive outlook for 2025.Company Guidance
In the call discussing Valneva’s Full Year 2024 Results and Corporate Update, the company highlighted several key metrics and forward-looking statements. Valneva reported achieving double-digit year-on-year sales growth with sales exceeding €160 million, aligned with their 2024 guidance. The company's cash position at year-end was strong at nearly €170 million, aided by a successful placement of nearly €60 million and the sale of a priority review voucher. Regulatory achievements included three additional IXCHIQ approvals and significant label extensions. Valneva also augmented its pipeline with a Phase 2 Shigella program and anticipates multiple data readouts and product approvals in 2025. Looking ahead, they expect the Lyme vaccine candidate, VLA15, to reach a first data readout by the end of 2025, with regulatory filings anticipated for 2026 and potential approvals in 2027. Valneva also targets continued revenue growth from IXIARO, DUKORAL, and IXCHIQ, with a focus on strategic R&D investments supported by additional grant funding.Double-Digit Sales Growth
Achieved targeted double-digit year-on-year sales growth, with sales above €160 million, aligning with the 2024 guidance.
Strong Financial Position
Solid cash position at year-end, close to €170 million, with a significantly lower operating cash burn.
Regulatory Success
Three additional IXCHIQ approvals and a significant number of upcoming label extensions around IXCHIQ.
Pipeline Expansion
Achieved strategic objective by augmenting the pipeline with a leading Phase 2 Shigella program.
Product Launches and Partnerships
Expanded access to IXCHIQ with launches in Canada, Europe, and the UK, and entered a new Asian partnership for key endemic markets.
Successful Financial Transactions
Successful placement of almost €60 million and sale of a priority review voucher for €103 million.
Strong IXIARO Sales
IXIARO sales grew by 28%, reaching €94.1 million compared to €73.5 million in 2023.
---
GB:0OB3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0OB3 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | €3.20 | €3.36 | +5.00% |
| Nov 07, 2024 | €2.59 | €2.50 | -3.47% |
| Aug 13, 2024 | €3.11 | €3.35 | +7.72% |
| May 07, 2024 | €3.44 | €3.42 | -0.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Valneva SE (GB:0OB3) report earnings?
Valneva SE (GB:0OB3) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Valneva SE (GB:0OB3) earnings time?
Valneva SE (GB:0OB3) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Valneva SE stock?
The P/E ratio of Valneva is N/A.
What is GB:0OB3 EPS forecast?
GB:0OB3 EPS forecast for the fiscal quarter 2025 (Q1) is -0.13.
---